Search Results - "Drach, J"

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review by Fonseca, R, Bergsagel, P L, Drach, J, Shaughnessy, J, Gutierrez, N, Stewart, A K, Morgan, G, Van Ness, B, Chesi, M, Minvielle, S, Neri, A, Barlogie, B, Kuehl, W M, Liebisch, P, Davies, F, Chen-Kiang, S, Durie, B G M, Carrasco, R, Sezer, Orhan, Reiman, Tony, Pilarski, Linda, Avet-Loiseau, H

“…Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several subtypes of the disease have been identified at the…”
Get full text

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) by Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, Ludwig, H

“…This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in…”
Get full text

Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study by Cavalli, F., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., Raderer, M., Mayer, J., Pereira, J., Tumyan, G., Okamoto, R., Nakahara, S., Hu, P., Appiani, C., Nemat, S., Robak, T.

Get full text

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis by Lamm, W, Willenbacher, W, Lang, A, Zojer, N, Müldür, E, Ludwig, H, Schauer-Stalzer, B, Zielinski, C. C, Drach, J

“…Bortezomib-dexamethasone (Btz/Dex) is an active regimen in patients with multiple myeloma and has been used in few patients with amyloidosis. Here, we report a…”
Get full text

Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma by Lamm, W, Drach-Schauer, B, Eder, S, Drach, J

“…Bortezomib (Btz) has emerged as a standard of care in the treatment of patients with multiple myeloma (MM), but Btz-induced peripheral neuropathy (PNP) has a…”
Get more information

Serum and urinary levels of CD222 in cancer: origin and diagnostic value by Vicikova, K, Petrovcikova, E, Manka, P, Drach, J, Stockinger, H, Leksa, V

“…The mannose 6-phosphate/insulin-like growth factor 2 receptor (CD222, M6P/IGF2R) is a multifunctional transmembrane type I receptor, mostly localized…”
Get more information

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Kaufmann, Hannes, Raderer, Markus, Wöhrer, Stefan, Püspök, Andreas, Bankier, Alexander, Zielinski, Christoph, Chott, Andreas, Drach, Johannes

“…We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with…”
Get full text

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion by SAGASTER, V, LUDWIG, H, KAUFMANN, H, ODELGA, V, ZOJER, N, ACKERMANN, J, KÜENBURG, E, WIESER, R, ZIELINSKI, C, DRACH, J

“…Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested that bortezomib may be active even in the presence of adverse prognostic…”
Get full text

Design, Synthesis, and Antiviral Evaluations of 1-(Substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as Nonnucleoside Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole by Porcari, Anthony R., Devivar, Rodrigo V., Kucera, Louis S., Drach, John C., Townsend, Leroy B.

“…We have recently reported that certain ribosylated polyhalogenated benzimidazoles are potent and selective inhibitors of HCMV replication at noncytotoxic…”
Get full text

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma by Wöhrer, S., Püspök, A., Drach, J., Hejna, M., Chott, A., Raderer, M.

“…Background: Diffuse large B-cell lymphoma (DLBCL) of the stomach is a relatively common disease. Recently, chemotherapy consisting of doxorubicin,…”
Get full text

Design, Synthesis, and Antiviral Activity of α-Nucleosides:  d- and l-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles by Migawa, Michael T., Girardet, Jean-Luc, Walker, John A., Koszalka, George W., Chamberlain, Stanley D., Drach, John C., Townsend, Leroy B.

“…Several 2-substituted α-d- and α-l-lyxofuranosyl and 5-deoxylyxofuranosyl derivatives of 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)benzimidazole…”
Get full text

Expression of MUM1 IRF4 mRNA as a prognostic marker in patients with multiple myeloma by Heintel, D, Zojer, N, Schreder, M, Strasser-Weippl, K, Kainz, B, Vesely, M, Gisslinger, H, Drach, J, Gaiger, A, Jäger, U, Ludwig, H

Get full text

Design, Synthesis, and Biological Evaluation of Tricyclic Nucleosides (Dimensional Probes) as Analogues of Certain Antiviral Polyhalogenated Benzimidazole Ribonucleosides by Zhu, Zhijian, Lippa, Blaise, Drach, John C, Townsend, Leroy B

“…The polyhalogenated benzimidazole nucleosides 2,5,6-trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB) and the 2-bromo analogue (BDCRB) were synthesized in…”
Get full text

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP) by Wöhrer, S., Drach, J., Hejna, M., Scheithauer, W., Dirisamer, A., Püspök, A., Chott, A., Raderer, M.

“…Background: Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively common type of lymphoma arising in various tissues throughout the human body…”
Get full text

Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma by Wöhrer, S., Chott, A., Drach, J., Püspök, A., Hejna, M., Hoffmann, M., Raderer, M.

“…Background: Enteropathy-type intestinal T-cell lymphoma (ETCL) is a highly aggressive disease with poor response to conventional CHOP (cyclophosphamide,…”
Get full text

In vivo effects of imatinib mesylate on human haematopoietic progenitor cells by Agis, H., Jaeger, E., Doninger, B., Sillaber, C., Marosi, C., Drach, J., Schwarzinger, I., Valent, P., Oehler, L.

“…Background  Imatinib mesylate has considerable antineoplastic activity in patients with chronic myeloid leukaemia (CML) and some solid tumours. Although…”
Get full text

Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action by BIRON, Karen K, HARVEY, Robert J, STANAT, Sylvia C, DRACH, John C, TOWNSEND, Leroy B, KOSZALKA, George W, CHAMBERLAIN, Stanley C, GOOD, Steven S, SMITH, Albert A, DAVIS, Michelle G, TALARICO, Christine L, MILLER, Wayne H, FERRIS, Robert, DORNSIFE, Ronna E

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Synthesis and Antiviral Activity of Novel Erythrofuranosyl Imidazo[1,2-a]pyridine C-Nucleosides Constructed via Palladium Coupling of Iodoimidazo[1,2-a]pyridines and Dihydrofuran by Gudmundsson, Kristjan S, Williams, John D, Drach, John C, Townsend, Leroy B

“…2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB) and certain analogues have shown significant activity against human cytomegalovirus. The metabolic…”
Get full text

Synthesis and Antiviral Evaluation of Trisubstituted Indole N-Nucleosides as Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB) by Chen, Jiong J, Wei, Yuan, Drach, John C, Townsend, Leroy B

“…2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB) and 2-bromo-5,6-dichloro-1-(β-d-ribofuranosyl)benzimidazole (BDCRB) are nucleosides that exhibit…”
Get full text

Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance by Chiba, P, Ecker, G, Schmid, D, Drach, J, Tell, B, Goldenberg, S, Gekeler, V

“…The sodium channel blocker propafenone and a series of analogs have been identified as effective modulators of P-glyco-protein-mediated multidrug resistance in…”
Get more information